|Therapeutic cell engineering with surface-conjugated synthetic nanoparticles|
MT Stephan, JJ Moon, SH Um, A Bershteyn, DJ Irvine
Nature medicine 16 (9), 1035-1041, 2010
|Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses|
JJ Moon, H Suh, A Bershteyn, MT Stephan, H Liu, B Huang, M Sohail, ...
Nature materials 10 (3), 243-251, 2011
|HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa|
JW Eaton, LF Johnson, JA Salomon, T Bärnighausen, E Bendavid, ...
PLoS medicine 9 (7), e1001245, 2012
|Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models|
BL Jewell, E Mudimu, J Stover, D Ten Brink, AN Phillips, JA Smith, ...
The lancet HIV 7 (9), e629-e640, 2020
|Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical …|
JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ...
The Lancet Global Health 2 (1), e23-e34, 2014
|Bioactive hydrogels with an ordered cellular structure combine interconnected macroporosity and robust mechanical properties|
AN Stachowiak, A Bershteyn, E Tzatzalos, DJ Irvine
Advanced Materials 17 (4), 399-403, 2005
|Sustainable HIV treatment in Africa through viral-load-informed differentiated care|
A Phillips, A Shroufi, L Vojnov, J Cohn, T Roberts, T Ellman, K Bonner, ...
Nature 528 (7580), S68-S76, 2015
|Polymer-supported lipid shells, onions, and flowers|
A Bershteyn, J Chaparro, R Yau, M Kim, E Reinherz, L Ferreira-Moita, ...
Soft matter 4 (9), 1787-1791, 2008
|Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine|
A Bershteyn, MC Hanson, MP Crespo, JJ Moon, AV Li, H Suh, DJ Irvine
Journal of controlled release 157 (3), 354-365, 2012
|Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy|
AR Kirtane, O Abouzid, D Minahan, T Bensel, AL Hill, C Selinger, ...
Nature communications 9 (1), 1-12, 2018
|HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making|
HIV Modelling Consortium Treatment as Prevention Editorial Writing Group
PLoS Medicine 9 (7), e1001259, 2012
|Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial|
RV Barnabas, ER Brown, A Bershteyn, HC Stankiewicz Karita, ...
Annals of internal medicine 174 (3), 344-352, 2021
|Nanobiomechanics of repair bone regenerated by genetically modified mesenchymal stem cells|
K Tai, G Pelled, D Sheyn, A Bershteyn, L Han, I Kallai, Y Zilberman, ...
Tissue Engineering Part A 14 (10), 1709-1720, 2008
|Sexual partnership age pairings and risk of HIV acquisition in rural South Africa|
A Akullian, A Bershteyn, D Klein, A Vandormael, T Bärnighausen, ...
AIDS (London, England) 31 (12), 1755, 2017
|Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral …|
JW Eaton, N Bacaër, A Bershteyn, V Cambiano, A Cori, RE Dorrington, ...
The Lancet Global Health 3 (10), e598-e608, 2015
|Point-of-care HIV viral load testing: an essential tool for a sustainable global HIV/AIDS response|
PK Drain, J Dorward, A Bender, L Lillis, F Marinucci, J Sacks, A Bershteyn, ...
Clinical microbiology reviews 32 (3), e00097-18, 2019
|Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry|
M Kim, L Song, J Moon, ZYJ Sun, A Bershteyn, M Hanson, D Cain, ...
Journal of Biological Chemistry 288 (44), 31888-31901, 2013
|Age-dependent partnering and the HIV transmission chain: a microsimulation analysis|
A Bershteyn, DJ Klein, PA Eckhoff
Journal of the Royal Society Interface 10 (88), 20130613, 2013
|Implementation and applications of EMOD, an individual-based multi-disease modeling platform|
A Bershteyn, J Gerardin, D Bridenbecker, CW Lorton, J Bloedow, ...
Pathogens and disease 76 (5), fty059, 2018
|Methods and compositions for localized agent delivery|
DJ Irvine, M Stephan, M Jaehyun, A Bershteyn
US Patent 9,283,184, 2016